Date: 2016-07-29
Type of information: Clinical research agreement
Compound:
Company: Diamyd Medical (Sweden) Janssen Research & Development, a J&J company (USA - NJ) the Juvenile Diabetes Research Foundation (JDRF) (USA) the University of Alabama at Birmingham (USA)
Therapeutic area: Autoimmune diseases - Metabolic diseases
Type agreement: clinical research
Action mechanism:
Disease: type 1 diabetes
Details: * On July 29, 2016, Diamyd Medical announced that it has signed an agreement with Janssen Research & Development, the Juvenile Diabetes Research Foundation (JDRF) and the University of Alabama at Birmingham regarding the ongoing clinical trial “Effect of GABA or Combination GABA/GAD on the Progression of Type 1 Diabetes Mellitus in Children” (NCT02002130). The agreement entails that Janssen Research & Development and JDRF will support the trial with approximately $ 600 000 to be used to study GABA-biomarkers and to increase the number of patients in the trial.
Financial terms:
Latest news:
